-
艾媒咨询|2021-2022年中国医美器械产业运行及投资决策分析报告
本报告研究涉及企业/品牌/案例:科医人,复星医药,奇致激光,半岛医疗
伴随着医美市场规模的持续扩大,中国医美器械行业发展前景可期。数据显示,预计2021年中国医美器械市场规模将超过500亿元,同比增长27.8%。从细分赛道来看,近年来,微创和无创已逐渐成为医疗美容的趋势,这就推动了以激光、超声波等能量源为代表的光电类医美器械的发展。从市场格局来看,中国正规医美机构设备的市场份额80%是进口品牌,且中高端市场被飞顿、塞诺龙等海外龙头企业占领。为了改变这一局面,国家及地方先后出台政策鼓励本土医美器械品牌的发展,同时,国有品牌也通过加大自主研发投入和投资并购来扩大市场份额,未来随着下游扩张、需求渗透、技术更新等因素有望加速进口替代。
With the continuous expansion of the medical beauty market, the development prospect of the medical beauty equipment industry in China is promising. According to the data, it is estimated that in 2021, the market size of medical devices in China will exceed 50 billion yuan, with a year-on-year growth of 27.8%. From the perspective of subdivision, in recent years, minimally invasive and non-invasive have gradually become the trend of medical beauty, which promotes the development of photoelectric medical beauty devices represented by laser, ultrasonic and other energy sources. From the perspective of market structure, 80% of the market share of China's regular medical and beauty institutions' equipment is imported brands, and the medium and high-end market is occupied by overseas leading enterprises such as feton and sinolon. In order to change this situation, the state and local governments have successively issued policies to encourage the development of local medical and beauty equipment brands. At the same time, the state-owned brands also expand their market share by increasing independent R & D investment and investment in M & A. in the future, with the downstream expansion, demand penetration, technology update and other factors, it is expected to accelerate the import substitution. -
艾媒咨询|2020年3-4月中国母婴行业运行状况及企业商情动态双月度报告
本报告研究涉及企业/品牌/案例:戴维医疗、仟源医疗、贝贝网、宝宝树。
2020年疫情期间,在线上的母婴产品购物占比10.1%,其中宝宝树平台的全网月活渗透率最高。艾媒咨询分析师认为,在直播电商等购物模式的发展下,各大母婴门店在有节奏地部署线上转型,但从目前的消费习惯来看,线下渠道依旧是母婴产品消费的主要战场。
During the 2020 epidemic, online shopping for maternal and child products accounted for 10.1%, and the Babytree platform had the highest monthly active penetration rate across the entire network. iiMedia Research believe that under the development of live e-commerce and other shopping models, major maternal and child stores are gradually deploying online transformation, but from the current consumption habits, offline channels are still maternal and child product consumption Main battlefield. -
艾媒咨询|2020年中国细胞生物产业和商业应用分析报告
本报告研究涉及企业/品牌/案例:华夏源、复星医药。
中国细胞生物产业类型呈现多样化趋势,细胞生物临床研究不断深化,伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成,生态圈的完善将在很大限度上推动产业快速发展。数据显示,中国细胞治疗企业融资金额不断增加,从2014年的0.2亿元增长至2019年的28.9亿元。其中,2018年中国细胞治疗企业融资额同比增长706.8%,呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇,同时也有挑战并存。后续产业的发展,将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局,企业也应积极开展生态合作以及更为密切关注市场需求动向,将疗法和新一代医疗创新技术深度融合,实现市场产品多元化与差异化,并推出独特性的精准治疗,从而最大限度地释放产业价值。
The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value. -
艾媒报告|2020中国独角兽TOP100榜单及标杆企业研究报告
本报告研究涉及企业/品牌/案例:乂学教育-松鼠Ai 1对1,每日优鲜,美菜网,微医,联影医疗,快手,云从科技,滴滴出行,小鹏汽车,菜鸟网络,苏宁金融,柔宇科技,奇安信;其他提及企业/品牌:阿里巴巴,腾讯,京东,蚂蚁金服,京东数科,橙行智动,字节跳动 ,智者天下,度小满,小桔科技,商汤科技,喜马拉雅,地平线,陆金所,云杉世界,搜车网 ,满帮集团,云从科技,深兰科技 ,威马汽车,银联商务,车和家,大疆创新,微医云,小船出海,悦易网络,微众银行,优必选,猿力教育,寒武纪元,比特大陆,柔宇科技,行吟信息,拜腾汽车,小屋信息 ,优客工场,准时达,车好多,自如,智车优行,依图科技,葆扬投资,彬讯科技,钱大妈,一起作业,呯嘭智能,涂鸦科技,奥比中光,洋码头,麒麟合盛,途家在线,密境和风,图森未来,蚂蜂窝,纳恩博,悦畅科技,特斯联,新潮传媒,优行科技,第四范式,碳云智能,同盾科技,一点网聚,云知声,随手科技,八戒网络,数梦工场,首约科技,小马智行,虫极科技,联易融,诺禾致源,魅族,博鳌纵横,找钢网,圆心科技,影谱科技,氪空间,越海全球,花旺在线,快跑信息,丰巢科技,医云科技,淘友天下,华云数据,沪江教育,酒仙网,易动纷享,羽扇智,适赫物流,辣妈帮,贝贝集团,斑马网络,初速度,汇通天下,连尚网络
iiMedia Research(艾媒咨询)数据显示,2020年中国独角兽TOP100企业中,地域方面,北京、上海和深圳分别出现39、20和15家独角兽企业,总占比达74%;行业领域方面,人工智能与电商零售领域的独角兽企业发展较为迅速,上榜企业达33家。受益于新兴技术以及庞大的消费人群,与大众消费相关的独角兽企业发展较快,数量占到46%。艾媒咨询分析师认为,在2020年新冠疫情的影响下,中国宏观经济下行压力加剧,独角兽企业也将面临全新的机遇和挑战,一方面不少独角兽企业将受益于国家新老基建投资以及内需扩容提质等政策刺激快速发展,另一方面在全球经济增速放缓的情况下独角兽企业也将面临更激烈的竞争,生存发展压力加剧。
Among the unicorn TOP100 companies in China in 2020, Beijing, Shanghai and Shenzhen have 39, 20, and 15 unicorn companies accounted for 74% of the total; in the field of industry, unicorn companies in the field of artificial intelligence and e-commerce retail developed rapidly, with 33 companies on the list. Benefiting from emerging technologies and a large consumer population, unicorn companies related to mass consumption have developed rapidly, accounting for 46% of the total. iiMedia Consulting analysts believe that under the influence of the new crown epidemic in 2020, China's macroeconomic downward pressure will increase, and unicorn companies will also face new opportunities and challenges. On the one hand, many unicorn companies will benefit from national infrastructure Policies such as investment and domestic demand expansion and quality spur rapid development. On the other hand, with the global economic growth slowing down, unicorn companies will also face more intense competition and intensify the pressure on survival and development. -
艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告
本报告研究涉及企业/品牌/案例:白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业,培力控股,盛实百草,芍花堂,亳药千草,汇群中药
国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research(艾媒咨询)调查显示,有49%的受访用户倾向中医药治疗,与西药基本持平。2018年中国中药材市场规模达1246亿元,同比增长22.40%,在巨大的需求驱动下,中药材种植面积扩大,药材产量将会持续增长。
中药材主要包括上游种植、养殖市场,中游流通市场和下游销售市场三大环节。目前,中药饮片和中成药生产是中药产业的核心,主要包括中药加工,包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面,行业销售收入增速分别在2016和2018年触底回升,华润三九、中国中药、红日药业等上市公司表现良好;中药配方颗粒方面,2006-2016年,中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%,中药配方颗粒或将成为中药饮片加工行业应用广泛的产品;中成药方面,随着国家医改政策的推行,中成药消费需求趋于合理,中成药产量开始回落,但仍处于一个比较高的产量水平,云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。
Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well. -
艾媒报告|2019-2020全球区块链技术布局与商业投资趋势研究报告
本报告研究涉及企业/品牌/案例:量子保,边界智能,能链科技,融链,根源链,水滴互助,智链万源,趣链科技,迅雷,MONERO,北京链安,阿里健康,金色财经,互链脉搏,巴比特,挖链网,鸵鸟区块链
iiMedia Research(艾媒咨询)数据显示,截至2019年8月全球各国政府推动的区块链项目数量达154项,全球区块链产业累计投融资规模达103.69亿美元。经过十年的发展,区块链技术在全球领域内已实现金融、政务、医疗、工业制造等多个领域不同程度的应用,社会对区块链的价值和适用场景的认识不断提高。具体表现为产业资本回归理性,各国政府重视程度上升,产业逐渐由野蛮生长期迈入规范有序发展阶段。虽然区块链产业前景广阔,但受限于尚未形成的行业技术标准体系,区块链技术在应用和推广方面受到诸多限制。艾媒咨询分析师认为,作为下一代互联网的关键技术,各国政府以及巨头企业将加大力度布局区块链的研究和应用,对于行业标准制定权的争夺趋于激烈。中国在区块链领域有良好的发展基础,相关专利申请数量全球第一,随着政策的进一步放开,中国区块链产业将迎来快速发展阶段,有望全方位步入全球区块链产业第一梯队。
According to the data of iiMedia research, as of August 2019, the number of blockchain projects promoted by governments around the world has reached 154, and the cumulative investment and financing scale of the global blockchain industry has reached US $10.369 billion. After ten years of development, blockchain technology has been applied in many fields, such as finance, government affairs, medical treatment, industrial manufacturing and so on, and the society's understanding of the value and applicable scenarios of blockchain has been constantly improved. The specific performance is that industrial capital returns to rationality, governments of all countries pay more attention to it, and the industry gradually moves from the barbaric growth stage to the standardized and orderly development stage. Although the blockchain industry has a broad prospect, but limited by the industry technology standard system that has not yet formed, the application and promotion of blockchain technology are subject to many restrictions. iiMedia consulting analysts believe that as the key technology of the next generation of Internet, governments and giant enterprises will increase efforts to layout the research and application of blockchain, and the competition for the right to formulate industry standards tends to be fierce. China has a good development foundation in the field of blockchain, and the number of related patent applications ranks first in the world. With the further liberalization of policies, China's blockchain industry will usher in a stage of rapid development, and it is expected to step into the first echelon of global blockchain industry in an all-round way. -
艾媒报告 |2019中国基因测序产业研究和商业应用分析报告
本报告研究涉及企业/品牌/案例:Thermo Fisher(美),Illuminate(美),(瑞士),Stem cells(加),R&D(瑞士),华大基因,贝瑞基因,金城检验,美吉生物,恒创基因,基研生物,谱元科技,景杰生物,燃石生物,基迪奥生物,谷和信息,圣庭生物,天昊生物,诺禾致源,百迈克生物,思博奥科,赛莱拉,赛贝、北昊干细胞,达安基因,燃石医学、泛生子基因、世和基因,臻和生物,鹍远基因,23魔方,瀚海基因,百奥赛图,克睿基因,药明明码,裕策生物
随着基因测序的技术推进,基因测序开始应用于生物、侦查、无创产前检测和肿瘤治疗等场景中。技术的市场化应用吸引了全球资本方关注,iiMedia Research(艾媒咨询)数据显示,2018年全球医疗健康领域资本市场中,生物技术领域获得309件投资案共138亿元美元,领跑所有细分领域。中国生物技术科研研发实力厚积薄发,特别是科创板推动了基因测序市场的进一步升温,越来越多的生物创业公司在创业初期已获得高额融资。目前,中国已经基本形成了完整的上中下游产业链,但除了华大基因、贝瑞基因等少数头部企业,中国基因测序企业多数分布于产业链中下游,并且开始出现产品同质化等问题。艾媒咨询分析师认为,第二代测序技术的普及以及第三代测序技术的加紧研发将使得基因测序作为一个更加普遍的技术手段应用到不同场景之中,但目前仍然存在监管体系不够完善、道德伦理风险等问题。企业方面应当专注研究核心技术专利,通过人才储备和差异化竞争获得市场优势;行业和相关部门应当尽快完善行业规范管理体系,推动产业健康发展。
With the advancement of gene sequencing technology, gene sequencing began to be used in biological, detection, noninvasive prenatal testing and tumor treatment and other scenarios. The market-oriented application of technology has attracted global capital attention, with iiMedia Research leading all segments of the world in 309 investments in the global healthcare capital markets in 2018, with 309 investments, according to iiMedia Research. China's biotechnology research and development strength thick and thin hair, especially the science and technology board to promote the gene sequencing market further heating up, more and more bio-startup companies in the early stage of the start-up has been high financing. At present, China has basically formed a complete upstream and downstream industrial chain, but in addition to Huada gene, Berry gene and a few other head enterprises, Most of China's gene sequencing enterprises are distributed in the middle and lower reaches of the industrial chain, and began to appear product homogenization and other issues. Ai media consulting analysts believe that the popularity of second-generation sequencing technology and the third generation of sequencing technology will make gene sequencing as a more common technical means to apply to different scenarios, but there are still problems such as inadequate regulatory system, ethical risks. Enterprises should focus on researching core technology patents and gain market advantages through talent pool and differentiated competition, and industries and related departments should improve the industry standard management system as soon as possible to promote the healthy development of the industry. -
艾媒报告 |2019中国人造肉产业研究与消费者行为调查报告
本报告研究涉及企业/品牌/案例:Beyond Meat,Impossible Foods,杜邦,Ripple Foods,Bolthouse Farms,Roquette,Field Roast,Gardein,Mosa Meat,Modern Meadow,Finless Foods,烟台双塔食品,深圳齐善食品,宁波素莲素食,江苏鸿旭食品,万达财富,来伊份,登海种业,大北农,新开疆,京粮控股,四环生物,九芝堂,ST天宝,友好集团,爱普股份,丰乐种业,北大荒,天士力,中源协和,大康农业,东宝生物,融捷健康,华宝股份,戴维医疗,千红制药,金健米业,圣济堂,济民制药,哈高科,国际医学,维维股份,海欣食品,复星医药,苏常柴A,瑞茂通
人造肉主要包括植物肉、培育肉和混合肉三类。随着全球肉类短缺危机、健康与环保的消费风潮、食品创新推动等因素带动人造肉产业发展,资本市场开始关注人造肉产业,例如,Beyond Meat上市股市表现良好,Impossible Foods已完成超过6.875亿美元的多轮融资。中国的人造肉市场也开始发展,艾媒商情舆情数据监测系统显示,广东网民最关注人造肉议题。在资本和舆论的带动下,A股市场人造肉版块的活跃,同时,各类人造肉的上游产业链如大豆、豌豆蛋白、胎牛血清等开始共同发展。iiMedia Research(艾媒咨询),36%的中国消费者并不了解人造肉,同时低于四成消费者愿意尝试人造肉。艾媒咨询分析师认为,人造肉要真正市场化普及仍需克服成本、技术、消费者心理因素等多重障碍。
Artificial meat mainly includes three types of plant meat, cultivated meat and mixed meat. With the global meat shortage crisis, the consumption trend of health and environmental protection, and the promotion of food innovation, the capital market has begun to focus on the artificial meat industry. For example, Beyond Meat listed stocks performed well, and Impossible Foods has completed more than 687.5 million. Multiple rounds of financing for the dollar. China's artificial meat market has also begun to develop, and the iiMedia Research business data analysis system shows that Guangdong netizens are most concerned about artificial meat issues. Driven by capital and public opinion, the artificial meat section of the A-share market is active. At the same time, the upstream industrial chains of various types of artificial meat, such as soybean, pea protein and fetal bovine serum, have begun to develop together. iiMedia Research, 36% of Chinese consumers do not know about artificial meat, and less than 40% of consumers are willing to try artificial meat. Ai Media Consulting analysts believe that the real marketization of artificial meat still needs to overcome multiple obstacles such as cost, technology and consumer psychological factors. -
艾媒研报|科创板:2019年科创板受理企业及影子股分析研究报告
本报告研究涉及企业/品牌包括:科前生物、安翰科技、和舰芯片、容百科技、利元亨、江苏北人、天奈科技、睿创微纳、晶晨股份、贝斯达、华兴源创、微芯生物、特宝生物、国盾量子、虹软科技、世纪空间、光峰科技、福光股份、鸿泉物联、木瓜移动、优刻得、博众精工、创鑫激光、聚辰股份、海尔生物、天准科技、晶丰明源、申联生物、南微医学、美迪西、紫晶存储、苑东生物、恒安嘉新、乐鑫科技、龙软科技、杰普特、热景生物、瀚川智能、威胜信息、安博通、铂力特、视联动力、博瑞医药
2019年3月份科创板受理的企业包括:科前生物、安翰科技、和舰芯片、容百科技、利元亨、江苏北人、天奈科技、睿创微纳、晶晨股份、贝斯达、华兴源创、微芯生物、特宝生物、国盾量子、虹软科技、世纪空间、光峰科技、福光股份、鸿泉物联、木瓜移动等 2019年4月份受理的企业包括:优刻得、博众精工、创鑫激光、聚辰股份、海尔生物、天准科技、晶丰明源、申联生物、南微医学、美迪西、紫晶存储、苑东生物、恒安嘉新、乐鑫科技、龙软科技、杰普特、热景生物、瀚川智能、威胜信息、安博通、铂力特、视联动力、博瑞医药等,相应的重点影子股包括: TCL集团、华域汽车、天风证券、通化东宝、千方科技等。
In March and April 2019, the science and technology innovation board accepted the following enterprises: Wuhan Keqian Biology Co,Ltd, Ankon Technologies Co. Ltd, Hejian Technology (Suzhou) Co, Ltd, Ningbo Ronbay New Energy Technology Co, Ltd, Guangdong Lyric Robot Automation Co, Ltd, Jiangsu Beiren Robot System Co,Ltd, Jiangsu Cnano Technology Co, Ltd,Raytron Technology Co,Ltd,Amlogic (Shanghai) Co,Ltd, Shenzhen Basda Medical Apparatus Co,Ltd,Suzhou Hyc Technology Co,Ltd , etc. In April 2019, the science and technology innovation board accepted the following enterprises: Montage Technology Co, Ltd, UCloud Technology Co, Ltd, Bozhon Precision Industry Technology Co,Ltd, Shanghai Shen Lian Biomedical Corporation, Shanghai Bright Power Semiconductor Co, Ltd, Suzhou Tztek Technology Co,Ltd, Giantec Semiconductor Corporation, QINGDAO HAIER BIOMEDICAL CO, LTD. , MAXPHOTONICS Co, Ltd, Amethystum Storage Technology Co,Ltd , etc.
- 1
- 2
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告